On February 19, 2020 NeuroVive Pharmaceutical AB reported that Year End Report January – December 2019 (Press release, NeuroVive Pharmaceutical, FEB 19, 2020, View Source;december-2019-301007315.html [SID1234554533])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Important events in 2019

KL1333

NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study
NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study
NeuroVive completes recruitment of healthy volunteers in the second part of its ongoing KL1333 clinical Phase Ia/b study
NV354

NeuroVive initiates NV354 preclinical safety studies and scales up compound production
NeuroSTAT

NeuroVive’s IND for clinical development of NeuroSTAT approved by FDA
NeuroSTAT receives Fast Track designation from the US Food and Drug Administration
Financials

NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds
NeuroVive receives SEK 28.2 Million in a directed new share issue
Strategy and communications

NeuroVive updates its strategy and sharpens its focus on primary mitochondrial diseases
NeuroVive hosts the company’s first Capital Markets Day
NeuroVive hosts the Mitochondria Day for the second time
Other

NeuroVive announces settlement in dispute with CicloMulsion AG
Important events after the reporting period

NeuroVive proposes a rights issue of approximately MSEK 74 before issue costs. The rights issue is guaranteed to 90%.
Financial information fourth quarter (Oct-Dec 2019)*

Net revenues: KSEK 49 (5)
Other operating income: KSEK 1,000 (1,009)
Loss before tax: KSEK 27,112 (19,978)
Loss per share: SEK -0.15 (-0.25)
Diluted loss per share: SEK -0.15 (-0.25)
Financial information full year 2019 (Jan-Dec 2019)*

Net revenues: KSEK 34 (5)
Other operating income: KSEK 3,500 (2,461)
Loss before tax: KSEK 77,000 (73,494)
Loss per share: SEK 0.45 (0.94)
Diluted loss per share: SEK 0.45 (0.94)
* APM Alternative perfomance measures, see definition on page 17 in the Report.

The complete Year End report is available for download below and through NeuroVive’s web site www.neurovive.com.

The information was submitted for publication, through the agency of the contact person set out below at 08:40 a.m. CET on 19 February 2020.

On February 18, 2020 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, reported that HOOKIPA’s management team will present and host one-on-one meetings at the SVB Leerink 9th Annual Global Healthcare Conference, taking place February 25 – 27, 2020 in New York (Press release, Hookipa Pharma, FEB 18, 2020, View Source [SID1234554413]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation: Tuesday, February 25, 2020 at 10:00 a.m. ET, Lotte New York Palace, Room Kennedy I
A live audio webcast of the presentation held at the SVB Leerink Healthcare Conference will be available within the Investors & Media section of HOOKIPA’s website at View Source An archived replay will be accessible for 30 days following the event.

On February 18, 2020 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 1:00 p.m. ET at the Lotte New York Palace hotel (Press release, Heron Therapeutics, FEB 18, 2020, View Source [SID1234554430]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Company’s website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.

On February 18, 2020 Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, reported that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25 at 9:30 a.m. ET (Press release, Gossamer Bio, FEB 18, 2020, View Source [SID1234554446]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the "Events and Presentations" page in the "Investors" section of the company’s website at View Source A replay of the webcast will be archived on the company’s website for 90 days following the presentation.

On February 18, 2020 VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") reported it will host a conference call on Friday, February 21 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2019, in conjunction with the filing of its annual report on Form 10-K for the fourth quarter and full year ended December 31, 2019 (Press release, VolitionRX, FEB 18, 2020, View Source [SID1234554462]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: VolitionRx Limited Fourth Quarter & Full Year 2019 Earnings and Business Update Conference Call
Date: Friday, February 21, 2020
Time: 8:30 a.m. Eastern time
U.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13699351

Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with David Vanston, Chief Financial Officer and Scott Powell, Executive Vice President, Investor Relations. The call will provide an update on recent developments and Volition’s activities, including details of new and ongoing clinical trials, important events which have taken place in 2019, and milestones for 2020 and beyond.

A live audio webcast of the conference call will also be available on the investor relations page of Volition’s corporate website at View Source In addition, a telephone replay of the call will be available until March 6, 2020. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13699351.